Posts tagged alethia biotherapeutics

Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5

Alethia Biotherapeutics announced today that the U.S. Food and Drug Administration has cleared its Phase 2 Investigational new drug (IND) application for AB-16B5, a potent inhibitor of the epithelial to mesenchymal transition (EMT).

NewsGuest UserMay 21, 2020alethia biotherapeutics, cancer treatment, phase 2